Kirstin Powel Novartis Cell and Gene Therapy

Kirstin is currently global head of quality operations for the Cell and Gene Therapy Unit, including quality responsibility for the overall supply chain from apheresis sites back to institutions. Kirstin joined Novartis in February, 2015, as part of the Cell and Gene Therapy unit with responsibility for ensuring consistent and phase-appropriate quality standards for viral vectors and viral gene therapy drug products. Prior to joining Novartis, Kirstin was employed by Lonza, AG in the Global Quality organization, with global quality oversight for biologics as well as cell and gene therapy products. Kirstin has had direct responsibility for cell therapy manufacturing and quality for over fifteen years.